These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16829658)

  • 1. BRCA1 and BRCA2 cancer risks.
    Antoniou AC; Pharoah PD; Easton DF; Evans DG
    J Clin Oncol; 2006 Jul; 24(20):3312-3; author reply 3313-4. PubMed ID: 16829658
    [No Abstract]   [Full Text] [Related]  

  • 2. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One risk fits all?
    De Bock GH; Mourits MJ; Oosterwijk JC
    J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility.
    Wolff TA; Wilson JE
    Am Fam Physician; 2006 Nov; 74(10):1759-60. PubMed ID: 17137007
    [No Abstract]   [Full Text] [Related]  

  • 5. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
    Loman N
    Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Spannuth WA; Thaker PH; Sood AK
    Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers.
    James PA; Harris M; Lindeman GJ; Mitchell G
    J Med Genet; 2008 Nov; 45(11):765-6. PubMed ID: 18978334
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer risks for BRCA1/2 carriers.
    Wacholder S; Struewing JP; Hartge P; Greene MH; Tucker MA
    Science; 2004 Dec; 306(5705):2187-91; author reply 2187-91. PubMed ID: 15622558
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal selection of individuals for BRCA mutation testing.
    Evans DG; Lalloo F; Eccles D
    J Clin Oncol; 2006 Jul; 24(20):3311; author reply 3311-2. PubMed ID: 16829657
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    Suthers GK
    ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inherited breast and ovarian cancers].
    Gerdes AM; Ejlertsen B
    Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
    Olopade OI
    Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancer. A risky business--assessing breast cancer risk.
    Levy-Lahad E; Plon SE
    Science; 2003 Oct; 302(5645):574-5. PubMed ID: 14576407
    [No Abstract]   [Full Text] [Related]  

  • 15. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risk assessment and the genetic counseling process: using hereditary breast and ovarian cancer as an example.
    Prucka SK; McIlvried DE; Korf BR
    Med Princ Pract; 2008; 17(3):173-89. PubMed ID: 18408385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receiving inconclusive genetic test results: an interpretive description of the BRCA1/2 experience.
    Maheu C; Thorne S
    Res Nurs Health; 2008 Dec; 31(6):553-62. PubMed ID: 18449940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
    Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.